iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. Tekijä Rehman, I, Evans, C, Glen, A, Cross, S, Eaton, C, Down, J, Pesce, G, Phillips, J, Yen, O, Thalmann, G, Wright, P, Hamdy, F

Nuclear iASPP may facilitate prostate cancer progression. Tekijä Morris, E, Cerundolo, L, Lu, M, Verrill, C, Fritzsche, F, White, M, Thalmann, G, ten Donkelaar, C, Ratnayaka, I, Salter, V, Hamdy, F, Lu, X, Bryant, R

Lack of expression of noggin and Dickkopf-1 (DKK-1) by prostate cancer cells determines the osteoblast response in bone metastasis Tekijä Rentsch, C, Schwaninger, R, Wetterwald, A, van der Horst, G, van Bezooijen, R, van der Pluijm, G, Lowik, C, Ackermann, K, Pyerin, W, Hamdy, F, Thalmann, G, Cecchini, MG

Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Tekijä Schwaninger, R, Rentsch, C, Wetterwald, A, van der Horst, G, van Bezooijen, R, van der Pluijm, G, Löwik, C, Ackermann, K, Pyerin, W, Hamdy, F, Thalmann, G, Cecchini, MG

The osteoblastic response by prostate cancer bone metastases is determined by the lack of expression of noggin and dickkopf-1 (DKK-1) Tekijä Rentsch, C, Schwaninger, R, Wetterwald, A, Van Der Horst, G, Van Bezooijen, R, Van Der Pluijm, G, Loewik, C, Ackermann, K, Pyerin, W, Hamdy, F, Thalmann, G, Cecchini, M

High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Tekijä van den Hoogen, C, van der Horst, G, Cheung, H, Buijs, J, Lippitt, J, Guzmán-Ramírez, N, Hamdy, F, Eaton, C, Thalmann, G, Cecchini, MG, Pelger, R, van der Pluijm, G

Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. Tekijä Gao, S, Bajrami, I, Verrill, C, Kigozi, A, Ouaret, D, Aleksic, T, Asher, R, Han, C, Allen, P, Bailey, D, Feller, S, Kashima, T, Athanasou, N, Blay, J, Schmitz, S, Machiels, J, Upile, N, Jones, T, Thalmann, G, Ashraf, S, Wilding, J, Bodmer, W, Middleton, MR, Ashworth, A, Lord, C